Creative Diagnostics has announced the expansion of its comprehensive range of Products for Hepatic Metabolism, providing pharmaceutical researchers and toxicologists with new liver-specific fractions to conduct critical in vitro metabolism studies. This development addresses fundamental challenges in drug safety evaluation, where liver metabolism plays a central role in both therapeutic efficacy and toxicity.
The liver serves as the primary organ for drug metabolism and the main site of drug-induced toxicity, accounting for over 50% of acute liver failure cases that lead to the withdrawal or restricted use of approved medications. Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs, including the kidneys, heart, brain, intestines, and lungs, as well as tumors. This systemic distribution means that liver metabolism impacts not just hepatic safety but potential toxicity throughout the body.
Harnessing drug-metabolite interactions between the liver and other organs can achieve desired therapeutic effects, but such interactions may also lead to unintended toxic side effects. For example, the pre-chemotherapy drug ifosfamide induces nephrotoxicity because, in addition to producing the intended antitumor metabolite 4-hydroxy-IFO, the liver generates the nephrotoxic metabolite chloroacetaldehyde. Therefore, interactions between the liver and other organs must be carefully considered and evaluated in drug metabolism and toxicity studies.
The expanded product line includes liver products from various species, such as humans, non-human primates (macaques and rhesus monkeys), dogs, rats, rabbits, and minipigs. Core products include Liver Cytosol, Liver Microsomes, and Liver S9 Fractions, which enable researchers to study hepatic metabolic processes with high precision and reproducibility. This multi-species approach helps bridge the gap between in vitro testing and in vivo outcomes, potentially reducing the risk of clinical failure.
"Precise metabolomic analysis is the cornerstone of successful drug development," said the Creative Diagnostics project manager. The company's comprehensive metabolic research solutions address challenges encountered during drug development by providing tools that better predict how drugs will behave in living systems. Researchers can learn more about the full catalog of Products for Hepatic Metabolism by visiting https://qbd.creative-diagnostics.com/products-for-hepatic-metabolism.html.
Most liver diseases result in varying degrees of hepatocyte damage and functional impairment, thereby profoundly affecting metabolic processes. The liver's primary metabolic functions fall into four categories: carbohydrate metabolism, lipid and fatty acid metabolism, protein and amino acid metabolism, and drug metabolism. By offering improved tools for studying these processes, Creative Diagnostics contributes to more accurate safety assessments that could prevent harmful drugs from reaching patients while accelerating the development of effective therapies.
